| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CEP dipeptide 1 is a 2-(omega-carboxyethyl)pyrrole (CEP) dipeptide analogue. Its primary biological activity is angiogenic, meaning it promotes the formation of new blood vessels. The compound is designed to mimic natural peptides involved in cellular signaling and repair processes. By enhancing collagen synthesis and reducing inflammation, CEP dipeptide 1 aids in the study of anti-aging mechanisms and skin barrier repair. It is used as a mediator of age-related macular degeneration (AMD), suggesting that its targets may include pathways involved in angiogenesis and inflammation relevant to retinal health. However, specific receptor or enzyme targets have not been conclusively identified in the available literature.
|
|---|---|
| ln Vitro |
CEP dipeptide 1 demonstrates potent in vitro angiogenic activity. As a CEP dipeptide analogue, the compound promotes the formation of new blood vessels in cell-based models of angiogenesis. It has been shown to enhance collagen synthesis and reduce inflammation, indicating its potential utility in tissue repair and regeneration. The compound's activity is relevant to the study of age-related macular degeneration (AMD), where abnormal angiogenesis plays a critical role. CEP dipeptide 1's stable and bioactive structure makes it a valuable tool for exploring therapeutic applications in wound healing, skin rejuvenation, and dermatological formulations. The compound is soluble in DMSO at 10 mM and is intended for research purposes only.
|
| ln Vivo |
In vivo activity data for CEP dipeptide 1 are limited. Based on its in vitro angiogenic activity and its role as a mediator of age-related macular degeneration, the compound may exert effects on blood vessel formation and tissue repair in living systems. The compound's ability to enhance collagen synthesis and reduce inflammation suggests potential benefits in wound healing and tissue regeneration models. However, comprehensive pharmacokinetic and pharmacodynamic studies in animal models have not been extensively reported. The compound is primarily used as a research tool for studying angiogenesis, wound healing, and dermatological applications rather than as a therapeutic candidate. Further research is needed to establish its in vivo efficacy and safety profile.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for CEP dipeptide 1 is not well-established in the literature, as the compound is primarily studied for its angiogenic activity in cell-based systems. Typical assays for evaluating angiogenic activity involve measuring endothelial cell proliferation, migration, and tube formation. In tube formation assays, human umbilical vein endothelial cells (HUVECs) or other endothelial cell lines are seeded on Matrigel-coated plates and treated with varying concentrations of CEP dipeptide 1 (typically 1-100 uM). After incubation for 4-18 hours at 37degC, tube formation is quantified by measuring total tube length, branch points, or number of closed loops using phase-contrast microscopy or image analysis software. For cell proliferation assays, BrdU incorporation or MTT assays are used to assess the compound's effects on endothelial cell growth.
|
| Cell Assay |
The in vitro cell-based assay for CEP dipeptide 1 involves culturing relevant cell lines such as human umbilical vein endothelial cells (HUVECs), fibroblasts, or keratinocytes. Cells are typically seeded in multi-well plates and treated with varying concentrations of the compound (1-100 uM) for 24-72 hours in appropriate growth media at 37degC with 5% CO2. For angiogenesis studies, endothelial cells are assessed for proliferation (BrdU or MTT assays), migration (wound healing or Boyden chamber assays), and tube formation on Matrigel. For dermatological research, fibroblasts are evaluated for collagen synthesis using ELISA or Western blot analysis, and keratinocytes are assessed for barrier function and differentiation markers. The compound is soluble in DMSO at 10 mM and has a purity of ≥95%.
|
| Animal Protocol |
In vivo animal studies for CEP dipeptide 1 have not been extensively documented in the literature. Based on the compound's angiogenic activity and potential applications in wound healing and dermatology, potential animal studies would typically involve administration of the compound via topical, subcutaneous, or intradermal routes in rodent models of wound healing, skin aging, or angiogenesis-related conditions. Dosing would be determined based on preliminary pharmacokinetic data and solubility profiles. Common endpoints in such studies would include evaluation of wound closure rates, assessment of collagen deposition and angiogenesis in tissue sections, and monitoring of general toxicity parameters. However, comprehensive in vivo efficacy and toxicity studies have not been widely reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CEP dipeptide 1 have not been fully characterized in the literature. The compound has a molecular weight of 381.42 g/mol and a molecular formula of C1₈H2₇N3O₆. It has a predicted density of 1.24 g/cm3 and is soluble in DMSO at 10 mM. For storage, the compound should be kept at -20degC. The compound has a purity of ≥95%. As a dipeptide, CEP dipeptide 1 may be susceptible to proteolytic degradation in biological systems, which could limit its stability and bioavailability. The compound's physicochemical properties suggest moderate lipophilicity, which may influence its absorption and distribution. However, detailed pharmacokinetic parameters such as half-life, clearance, and volume of distribution have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicity data for CEP dipeptide 1 are limited, as the compound is a research-use peptide and has not undergone extensive toxicological characterization. Standard safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment such as gloves and lab coats to prevent skin contact and inhalation of dust. The compound should be handled in a well-ventilated area. In case of accidental exposure, rinse affected areas with plenty of water and seek medical attention if irritation persists. Proper waste disposal procedures should be observed in accordance with local regulations. As with all research chemicals, exposure should be minimized and the compound should be stored securely at -20degC away from incompatible materials.
|
| References |
|
| Additional Infomation |
CEP dipeptide 1 (CAS#: 816432-15-2) is a synthetic dipeptide with the molecular formula C1₈H2₇N3O₆ and a molecular weight of 381.42. Also known as a 2-(omega-carboxyethyl)pyrrole (CEP) dipeptide analogue, this compound exhibits potent angiogenic activity and is used as a mediator in studies of age-related macular degeneration (AMD). The compound is designed to mimic natural peptides involved in cellular signaling and repair processes and holds significance in dermatological research for its potential to promote skin regeneration and protect against oxidative stress. By enhancing collagen synthesis and reducing inflammation, CEP dipeptide 1 aids in the study of anti-aging mechanisms and skin barrier repair. The compound has a purity of ≥95%, is soluble in DMSO at 10 mM, and should be stored at -20degC. It is intended for research purposes only. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C18H27N3O6
|
|---|---|
| Molecular Weight |
381.4235
|
| Exact Mass |
381.19
|
| CAS # |
816432-15-2
|
| PubChem CID |
92044401
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
1.251
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
27
|
| Complexity |
525
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)NCC(=O)N[C@@H](CCCCN1C=CC=C1CCC(=O)O)C(=O)OC
|
| InChi Key |
VBZGZUAKQLIUCN-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C18H27N3O6/c1-13(22)19-12-16(23)20-15(18(26)27-2)7-3-4-10-21-11-5-6-14(21)8-9-17(24)25/h5-6,11,15H,3-4,7-10,12H2,1-2H3,(H,19,22)(H,20,23)(H,24,25)/t15-/m0/s1
|
| Chemical Name |
3-[1-[(5S)-5-[(2-acetamidoacetyl)amino]-6-methoxy-6-oxohexyl]pyrrol-2-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~10 mg/mL (~26.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6218 mL | 13.1089 mL | 26.2178 mL | |
| 5 mM | 0.5244 mL | 2.6218 mL | 5.2436 mL | |
| 10 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
